Glycated Hemoglobin A
Rising HbA1c levels contribute to CV event risk in diabetes, CAD
CVD risk evaluation in prediabetes not improved by incorporating HbA1c
Aerobic exercise, not diet, improves diastolic function in type 2 diabetes, obesity
PHILADELPHIA — Adults with type 2 diabetes and obesity without CVD experienced dramatic metabolic improvements after a 12-week, low-calorie diet intervention but saw no change in diastolic function, which was only observed with an aerobic exercise intervention, according to data presented at the American Heart Association Scientific Sessions.
Glycemic management possible with small-molecule glucagon receptor antagonist
Evening eating may worsen heart health in women
FDA advisory committee rejects recommending approval of lower-dose empagliflozin for type 1 diabetes
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 14-2 against recommending approval of a supplemental new drug application for the SGLT2 inhibitor empagliflozin 2.5 mg as an oral medication adjunct to insulin therapy for adults with type 1 diabetes, with committee members citing uncertainty regarding the adjudication of diabetic ketoacidosis and a lack of adequate data to support evidence for safety and efficacy.